No Data
No Data
Yifang Biotechnology (688382.SH): The application for new drug release is currently being pushed forward according to plan.
On June 25th, Gelunhui reported that Yifang Biotechnology (688382.SH) stated on the investor Q&A platform that in December 2023, the market launch application for Garsorasib (D-1553 tablets) was accepted by the CDE, and it was included in the priority review program in January 2024. In June 2024, the new indication for Garsorasib (D-1553 tablets) was again included in the breakthrough therapy drug program by the CDE. The application for the new drug market is currently being promoted according to plan.
An Intrinsic Calculation For InventisBio Co., Limited (SHSE:688382) Suggests It's 22% Undervalued
Key Insights Using the 2 Stage Free Cash Flow to Equity, InventisBio fair value estimate is CN¥10.98 InventisBio is estimated to be 22% undervalued based on current share price of CN¥8.60 Analyst
Yifang Biotech (688382.SH): Net loss of 83.1777 million yuan in the first quarter
Gelonghui, April 29丨Yifang Biotech (688382.SH) released its first quarter report, with operating income of 8.06 million yuan, net loss of 83.1777 million yuan, deducting non-net loss of 83.1777 million yuan, and basic earnings per share of -0.14 yuan.
Yifang Biotech (688382.SH): 2023 net profit - $284 million
On April 25, Ge Longhui (688382.SH) released its 2023 annual report. During the reporting period, the company made every effort to promote clinical research and cooperative development of major products and made important progress. In 2023, it achieved operating income of 186 million yuan, net profit attributable to shareholders of listed companies - 284 million yuan, a year-on-year loss decrease of 41.26%. The loss margin was narrower compared to the same period last year, mainly due to the increase in the company's 2023 technical licensing and technical cooperation revenue.
InventisBio (SHSE:688382) Has Debt But No Earnings; Should You Worry?
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the permanent loss of capital.' It's only natural to consider a company's balance sheet wh
Yifang Biotech (688382.SH) Performance Report: Net loss of 289 million yuan in 2023
Gelonghui, Feb. 5 | Yifang Biotech (688382.SH) announced the 2023 Annual Results Report. During the reporting period, the company made every effort to promote clinical research and cooperative development of major products and made significant progress. It is expected that operating revenue (technical licensing and cooperation revenue for externally authorized products) will increase compared with the same period last year, and the net loss margin will decrease. The company's main products are still in the R&D stage, commercial production and sales have not yet been carried out, and product sales revenue has not been realized. During the reporting period, the company is expected to achieve operating income of 183.0 million yuan and net profit attributable to the owner of the parent company - 28,9
No Data